Magnetosomes as Potential Nanocarriers for Cancer Treatment.

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug delivery Pub Date : 2024-01-01 DOI:10.2174/1567201820666230619155528

Rawan Alsharedeh, Nid'a Alshraiedeh, Alaa A Aljabali, Murtaza M Tambuwala

{"title":"Magnetosomes as Potential Nanocarriers for Cancer Treatment.","authors":"Rawan Alsharedeh, Nid'a Alshraiedeh, Alaa A Aljabali, Murtaza M Tambuwala","doi":"10.2174/1567201820666230619155528","DOIUrl":null,"url":null,"abstract":"<p><p>Magnetotactic bacteria (MTBs) and their organelles, magnetosomes, are intriguing options that might fulfill the criteria of using bacterial magnetosomes (BMs). The ferromagnetic crystals contained in BMs can condition the magnetotaxis of MTBs, which is common in water storage facilities. This review provides an overview of the feasibility of using MTBs and BMs as nanocarriers in cancer treatment. More evidence suggests that MTBs and BMs can be used as natural nanocarriers for conventional anticancer medicines, antibodies, vaccine DNA, and siRNA. In addition to improving the stability of chemotherapeutics, their usage as transporters opens the possibilities for the targeted delivery of single ligands or combinations of ligands to malignant tumors. Magnetosome magnetite crystals are different from chemically made magnetite nanoparticles (NPs) because they are strong single-magnetic domains that stay magnetized even at room temperature. They also have a narrow size range and a uniform crystal morphology. These chemical and physical properties are essential for their usage in biotechnology and nanomedicine. Bioremediation, cell separation, DNA or antigen regeneration, therapeutic agents, enzyme immobilization, magnetic hyperthermia, and contrast enhancement of magnetic resonance are just a few examples of the many uses for magnetite-producing MTB, magnetite magnetosomes, and magnetosome magnetite crystals. From 2004 to 2022, data mining of the Scopus and Web of Science databases showed that most research using magnetite from MTB was carried out for biological reasons, such as in magnetic hyperthermia and drug delivery.</p>","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"1073-1081"},"PeriodicalIF":2.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567201820666230619155528","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Magnetotactic bacteria (MTBs) and their organelles, magnetosomes, are intriguing options that might fulfill the criteria of using bacterial magnetosomes (BMs). The ferromagnetic crystals contained in BMs can condition the magnetotaxis of MTBs, which is common in water storage facilities. This review provides an overview of the feasibility of using MTBs and BMs as nanocarriers in cancer treatment. More evidence suggests that MTBs and BMs can be used as natural nanocarriers for conventional anticancer medicines, antibodies, vaccine DNA, and siRNA. In addition to improving the stability of chemotherapeutics, their usage as transporters opens the possibilities for the targeted delivery of single ligands or combinations of ligands to malignant tumors. Magnetosome magnetite crystals are different from chemically made magnetite nanoparticles (NPs) because they are strong single-magnetic domains that stay magnetized even at room temperature. They also have a narrow size range and a uniform crystal morphology. These chemical and physical properties are essential for their usage in biotechnology and nanomedicine. Bioremediation, cell separation, DNA or antigen regeneration, therapeutic agents, enzyme immobilization, magnetic hyperthermia, and contrast enhancement of magnetic resonance are just a few examples of the many uses for magnetite-producing MTB, magnetite magnetosomes, and magnetosome magnetite crystals. From 2004 to 2022, data mining of the Scopus and Web of Science databases showed that most research using magnetite from MTB was carried out for biological reasons, such as in magnetic hyperthermia and drug delivery.

查看原文本刊更多论文

磁小体作为治疗癌症的潜在纳米载体

趋磁细菌（MTBs）及其细胞器--磁小体，是可能符合细菌磁小体（BMs）使用标准的令人感兴趣的选择。磁小体中含有的铁磁晶体可以调节 MTB 的磁向性，这在储水设施中很常见。本综述概述了在癌症治疗中使用 MTB 和 BM 作为纳米载体的可行性。更多证据表明，MTB 和 BMs 可用作常规抗癌药物、抗体、疫苗 DNA 和 siRNA 的天然纳米载体。除了提高化疗药物的稳定性外，将它们用作转运体还为向恶性肿瘤靶向输送单一配体或配体组合提供了可能性。磁小体磁铁矿晶体不同于化学制造的磁铁矿纳米颗粒（NPs），因为它们是即使在室温下也能保持磁化的强单磁畴。它们还具有较窄的尺寸范围和均匀的晶体形态。这些化学和物理特性对它们在生物技术和纳米医学中的应用至关重要。生物修复、细胞分离、DNA 或抗原再生、治疗剂、酶固定化、磁性热疗和磁共振对比度增强只是产生磁铁矿的 MTB、磁铁矿磁小体和磁小体磁铁矿晶体众多用途中的几个例子。从 2004 年到 2022 年，对 Scopus 和 Web of Science 数据库进行的数据挖掘显示，利用 MTB 产生的磁铁矿进行的大多数研究都是出于生物学原因，如磁性热疗和药物输送。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.10

自引率

4.20%

发文量

170

期刊介绍： Current Drug Delivery aims to publish peer-reviewed articles, research articles, short and in-depth reviews, and drug clinical trials studies in the rapidly developing field of drug delivery. Modern drug research aims to build delivery properties of a drug at the design phase, however in many cases this idea cannot be met and the development of delivery systems becomes as important as the development of the drugs themselves. The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance. The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.